New trials, publications, preprints and grants on this target, month by month.
Trial
OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma
1 Dec 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas
10 Nov 2026· EARLY_PHASE1 · NOT_YET_RECRUITING· CTGOV
Preprint
Fractional tumor burden refines prognostic stratification beyond MGMT status in glioblastoma after chemoradiotherapy.
29 Oct 2026· medRxiv : the preprint server for health sciences· PUBMED
Publication
MGMT promoter methylation as a molecular biomarker in neuro-oncology: current practices, challenges, and future directions.
13 Oct 2026· Journal of neuro-oncology· PUBMED
Publication
EpiDirect enables rapid bisulfite-free MGMT promoter methylation testing in IDH-wildtype glioblastoma with high agreement across established assays.
5 Oct 2026· Neuro-oncology advances· PUBMED
Trial
A Single-Arm, Open-Label, Multicenter Clinical Study of Teniposide Combined With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (nGBM) With MGMT Promotor Region Unmethylated
1 Oct 2026· NA · NOT_YET_RECRUITING· CTGOV
Publication
The Role of Noncoding RNA in MGMT-Positive Glioblastoma: A Narrative Review.
1 Oct 2026· Cancer medicine· PUBMED
Publication
Prognostic impact of blood group O in MGMT-methylated glioblastoma patients receiving radiochemotherapy with temozolomide and lomustine.
24 Sept 2026· Journal of neuro-oncology· PUBMED
Publication
Publisher Correction: Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial.
1 Sept 2026· Nature cancer· PUBMED
Publication
Survival Impact of Supramarginal Resection According to MGMT Promoter Methylation Status in Glioblastoma: A Systematic Review and Meta-analysis.
1 Sept 2026· JPMA. The Journal of the Pakistan Medical Association· PUBMED
Publication
Externally validated explainable 3D CNN ensemble model for non-invasive prediction of IDH and MGMT status in gliomas.
26 Aug 2026· Frontiers in oncology· PUBMED
Publication
20(S)-protopanaxadiol enhances temozolomide responsiveness in MGMT-expressing glioblastoma: Wnt/β-catenin attenuation and MGMT downregulation.
17 Aug 2026· Frontiers in medicine· PUBMED
Trial
STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation
10 Aug 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Glioblastoma MRI Dataset with Standardized Preprocessing, Expert-Validated Segmentation, and MGMT Profiling.
7 Aug 2026· Scientific data· PUBMED
Trial
Temozolomide in Aggressive Pituitary Neuroendocrine Tumors: A Latin American Multicenter Retrospective Cohort (TMZ-LATAM)
1 Aug 2026· NA · NOT_YET_RECRUITING· CTGOV
Publication
DNA methylation of silencer-annotated regions at the MGMT locus in the context of promoter and enhancer methylation in glioblastoma and melanoma brain metastases.
1 Aug 2026· Clinical epigenetics· PUBMED
Publication
Low-dose temozolomide combined with valproic acid in the treatment of an elderly patient with MGMT-methylated glioblastoma and multiple comorbidities: a case report.
30 Jul 2026· Frontiers in oncology· PUBMED
Publication
DLK1-35 Contributes to Temozolomide Resistance in Glioblastoma Through the miR-140-3p/NHE1/ERK-MGMT Axis.
23 Jul 2026· The Tohoku journal of experimental medicine· PUBMED
Publication
Extent of resection and survival in IDH-wildtype glioblastoma: interaction with MGMT status and chemoradiation.
23 Jul 2026· Journal of neuro-oncology· PUBMED
Publication
5-FU in combination with PARP inhibitor ABT-888 deregulates MGMT-dependent mismatch repair (MMR) pathway in MMR-proficient colorectal cancer stem cells by modulating MGMT/PARP1/MSH6 complex.
23 Jul 2026· Expert opinion on therapeutic targets· PUBMED
Publication
Prediction of MGMT promoter methylation in glioblastoma and grade 4 astrocytoma using fluid-suppressed chemical exchange saturation transfer MRI and machine learning-based segmentation.
23 Jul 2026· Frontiers in oncology· PUBMED
Publication
O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation-Guided Irinotecan-Based Therapy in Metastatic Colorectal Cancer: A Case Report.
21 Jul 2026· Cureus· PUBMED
Trial
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
16 Jul 2026· PHASE3 · RECRUITING· CTGOV
Publication
Integrating chemotherapy, radiotherapy, and O6-methylguanine-DNA methyltransferase (MGMT) status with deep-learning cellular tumor volumetry sharpens prediction of glioblastoma recurrence on postoperative MRI.
9 Jul 2026· Neuro-oncology advances· PUBMED
Publication
EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma.
8 Jul 2026· Science translational medicine· PUBMED
Trial
A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma
1 Jul 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
E3 ligase LMO7 promotes ALKBH2 ubiquitination to sensitize MGMT-deficient glioblastoma to temozolomide.
30 Jun 2026· Cell death & disease· PUBMED
Publication
Single Institution Retrospective Study to Determine Time to First True Progression in MGMT-Methylated Glioblastoma Patients Who Received Standard of Care.
29 Jun 2026· Journal of clinical medicine· PUBMED
Publication
Impact of weak MGMT promoter methylation on the prognosis of patients with newly diagnosed glioblastoma.
23 Jun 2026· Journal of neurosurgical sciences· PUBMED
Publication
Independent associations of MGMT promoter methylation and TERT promoter mutation with overall survival in glioblastoma: a single-center retrospective cohort study.
22 Jun 2026· Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology· PUBMED